Provided by Tiger Fintech (Singapore) Pte. Ltd.

Moleculin Biotech

0.8201
-0.0486-5.60%
Post-market: 0.8001-0.0199-2.43%19:50 EDT
Volume:487.21K
Turnover:393.17K
Market Cap:11.48M
PE:-0.07
High:0.8467
Open:0.8467
Low:0.7600
Close:0.8687
Loading ...

Moleculin Biotech: Expects Miracle Trial Accelerated to 2H 2025 With Potential for Accelerated Nda Process Beginning as Early as 2027

THOMSON REUTERS
·
08 Jan

Moleculin Biotech files to sell common stock, warrants, no amount given

TIPRANKS
·
14 Dec 2024

Moleculin Biotech Shares Rise After Announcing Preclinical Data for Annamycin Targeting Venetoclax-Resistant Leukemia

MT Newswires Live
·
12 Dec 2024

Moleculin Biotech Unveils New Corporate Presentation

TIPRANKS
·
18 Nov 2024

Moleculin Biotech Advances Annamycin for AML Treatment

TIPRANKS
·
18 Nov 2024

Moleculin Biotech announces new findings on Annamycin

TIPRANKS
·
18 Nov 2024

Moleculin Biotech Unveils New Corporate Presentation

TIPRANKS
·
14 Nov 2024

BRIEF-Moleculin Accelerates Planned Unblinded Data Readout For Miracle Phase 3 R/R Acute Myeloid Leukemia (AML) Pivotal Trial To H2 2025

Reuters
·
14 Nov 2024

Moleculin Biotech accelerates unblinding of Phase 3 efficacy data in AML

TIPRANKS
·
14 Nov 2024

Moleculin Biotech Inc - First Subject Treatment in Miracle Trial Expected Q1 2025

THOMSON REUTERS
·
14 Nov 2024

Moleculin Accelerates Planned Unblinded Data Readout for Miracle Phase 3 R/R Acute Myeloid Leukemia (Aml) Pivotal Trial to H2 2025

THOMSON REUTERS
·
14 Nov 2024

BRIEF-Moleculin Receives Institutional Review Board Approval For MIRACLE Phase 3 Pivotal Trial Of Annamycin In Combination With Cytarabine For The Treatment Of R/R Acute Myeloid Leukemia (AML)

Reuters
·
12 Nov 2024

Q3 2024 Moleculin Biotech Inc Earnings Call

Thomson Reuters StreetEvents
·
12 Nov 2024

Moleculin Biotech Reports Financial Highlights and Future Plans

TIPRANKS
·
12 Nov 2024

Moleculin Biotech Inc : Maxim Group Cuts Target Price to $8 From $20

THOMSON REUTERS
·
12 Nov 2024

Moleculin Biotech Inc reports results for the quarter - Earnings Summary

Reuters
·
11 Nov 2024

Moleculin Biotech GAAP EPS of -$2.85

seekingalpha
·
11 Nov 2024

Moleculin Biotech Q3 2024 GAAP EPS $(2.85) Misses $(2.80) Estimate, Cash And Cash Equivalents Of $9.4M, Expected To Be Sufficient To Fund Planned Operations Into Q1 2025

Benzinga
·
11 Nov 2024

Moleculin Biotech reports Q3 EPS ($2.85) vs. ($2.82) last year

TIPRANKS
·
11 Nov 2024

Moleculin Reports Third Quarter 2024 Financial Results and Provides Corporate Update

THOMSON REUTERS
·
11 Nov 2024